Tolleson Wealth Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Tolleson Wealth Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-33,250	Closed	-$3.39M	–	82
2023 Q2	$3.39M	Sell	33,250 -7,000	-17%	-$662K	0.82%	16
2023 Q1	$3.66M	Sell	40,250 -7,000	-15%	-$411K	0.95%	19
2022 Q4	$1.79M	Hold	47,250	–	–	0.49%	25
2022 Q3	$1.19M	Hold	47,250	–	–	0.36%	35
2022 Q2	$1.44M	Hold	47,250	–	–	0.41%	31
2022 Q1	$1.55M	Hold	47,250	–	–	0.46%	32
2021 Q4	$1.25M	Sell	47,250 -13,500	-22%	-$1.04M	0.34%	38
2021 Q3	$6.11M	Sell	60,750 -20,250	-25%	-$2.37M	1.73%	13
2021 Q2	$11.5M	Sell	81,000 -27,000	-25%	-$3.05M	3.09%	8
2021 Q1	$10.8M	Buy	+108,000	New	+$12.6M	3.25%	9

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Tolleson Wealth Management's RETA Position: Q3 2023 in Review

Tolleson Wealth Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 33,250 shares — an estimated $3.39M sold.

Tolleson Wealth Management first reported a position in RETA in Q1 2021 and held it in 10 quarters. The position peaked at $11.5M in Q2 2021. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Tolleson Wealth Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Tolleson Wealth Management sold 33,250 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $3.39M.
Tolleson Wealth Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2021 and held it in 10 quarters.
Tolleson Wealth Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $11.5M in Q2 2021.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Tolleson Wealth Management's 13F filing for Q3 2023, filed 14 Nov 2023.